GLI1

Zinc finger protein GLI1 · P08151 · GLI1 on Sugi Atlas →

6,170 patent compounds predicted against GLI1, 4,755 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Physalin B (SCHEMBL504410)	1.00	5/20
Alphitolic Acid (SCHEMBL1954405)	1.00	3/20
Ceanothic Acid (SCHEMBL965383)	0.76	3/20
SCHEMBL2845856	0.73	3/20
SCHEMBL3267062	0.71	3/20
SCHEMBL2993096	0.59	3/20
SCHEMBL3525117	0.57	3/20
SCHEMBL3434971	0.56	3/20
SCHEMBL967221	0.56	3/20
Ketoprofen (SCHEMBL572766)	0.53	3/20
Ketoprofen (SCHEMBL2286417)	0.53	3/20
Glochidonol (SCHEMBL3740114)	0.50	3/20
Lupane Anhydride (SCHEMBL2133330)	0.48	3/20
Lupane Anhydride (SCHEMBL2135129)	0.48	3/20
Lupane Anhydride (SCHEMBL2141349)	0.48	3/20
Lupane Anhydride (SCHEMBL3525136)	0.48	3/20
SCHEMBL3526193	0.48	3/20
SCHEMBL3433671	0.47	3/20
SCHEMBL3434963	0.47	3/20
SCHEMBL2687554	0.47	3/20

Clinical trials — most relevant to GLI1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1	PHASE4	COMPLETED
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	PHASE2	COMPLETED
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome	PHASE2	WITHDRAWN
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)	PHASE1/PHASE2	WITHDRAWN
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma	PHASE2	COMPLETED
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer	PHASE2	COMPLETED
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma	PHASE2	COMPLETED
Vismodegib for Treatment of Basal Cell Carcinoma	PHASE2	COMPLETED
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	PHASE2	COMPLETED
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)	PHASE2	COMPLETED
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer	PHASE2	COMPLETED
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	PHASE2	COMPLETED
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer	PHASE2	RECRUITING
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications	PHASE1/PHASE2	RECRUITING
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment	PHASE1	COMPLETED
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma	PHASE1	COMPLETED
A Study Of PF-04449913 Administered Alone In Select Solid Tumors	PHASE1	COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	PHASE1	COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	PHASE1	COMPLETED
Topical Itraconazole in Treating Patients With Basal Cell Cancer	EARLY_PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy	EARLY_PHASE1	COMPLETED
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer	EARLY_PHASE1	UNKNOWN
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.	nan	UNKNOWN
Children's and Adolescents' Medulloblastoma Molecular Subgroups in China	nan	UNKNOWN
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GLI1 binder may also engage these)

Protein	Name	Similarity
P47806	—	1.000	P47806 →
A2D4R4	—	1.000	A2D4R4 →
P14653	—	1.000	P14653 →
P08152	—	1.000	P08152 →
Q6XP49	—	1.000	Q6XP49 →
A2D649	—	1.000	A2D649 →
P51774	—	1.000	P51774 →
Q8NBF1	—	1.000	Q8NBF1 →
P11161	—	0.999	P11161 →
Q8K1M4	—	0.999	Q8K1M4 →
A2T6H5	—	0.999	A2T6H5 →
A2T7J2	—	0.999	A2T7J2 →
A1YG01	—	0.999	A1YG01 →
B3DLD3	—	0.999	B3DLD3 →
P55878	—	0.999	P55878 →
TET3	Methylcytosine dioxygenase TET3	0.998	landscape →
Q60793	—	0.998	Q60793 →
Q9QY61	—	0.998	Q9QY61 →
Q61575	—	0.998	Q61575 →
Q1KL10	—	0.997	Q1KL10 →
P19091	—	0.997	P19091 →
Q1KKW8	—	0.997	Q1KKW8 →
Q8K5B8	—	0.997	Q8K5B8 →
P43692	—	0.997	P43692 →
Q9ER75	—	0.997	Q9ER75 →
Q04888	—	0.997	Q04888 →
Q90ZH7	—	0.997	Q90ZH7 →
P70459	—	0.997	P70459 →
Q63449	—	0.997	Q63449 →
Q8NEA6	—	0.996	Q8NEA6 →